Gene therapy involves introducing genetic material deoxyribonucleic acid or ribonucleic acid (DNA or RNA) into the body as a treatment for disease. Often, this involves delivering a corrected copy of the gene to a patient’s cells to replace the defective one or modulating the expression of a patient’s genes, which could correct the disease. The field has changed significantly with the discovery of novel AAV vectors that are used to deliver genetic material to the cells. Adeno-assisted virus (AAV) vectors are small viruses that can carry genes to specific sites on a host cell. They show promise because, so far, they have not been shown to damage cells or to have any additional, permanent impact on their genomes, beyond delivering the gene. Clinical trials in gene therapy are showing potential for long-lasting treatment of diseases that cannot be addressed with current medicines.
Pfizer is committed to leading this technology by bringing together the expertise in AAV vector design and development with partnerships, in-house knowledge of disease biology, and manufacturing capabilities. Our current efforts include:
Collaborations with Spark Therapeutics Inc. on gene therapy for hemophilia and with 4D Molecular Therapeutics on gene therapy for cardiovascular diseases
Establishment of the Genetics Medicines Institute at Pfizer, led by Dr Michael Linden
These efforts establish a foundation upon which we intend to continue building our gene therapy programs and capabilities. With Pfizer’s commitment to rare monogenic diseases, we see gene therapy as a key pillar of our Rare Disease strategy and also envision its application to select central nervous system (CNS) and pulmonary diseases.